Rubicon Research Ltd Q2 FY2026 Concall Summary

Source transcript PDF: https://assets.stockscans.in/docs/33enfuidssl3c04o1rfjw3y3.pdf

Key Takeaways


Revenue Growth & Portfolio Dynamics

Parag Sancheti: "Over the last 12 years, what we have done well and continue to focus on One is portfolio, the approach of providing good science to meet unmet needs, which are also commercially attractive and building a therapy-focused company."

Margins: Gross Pressure, EBITDA Resilience

Parag Sancheti: "As we move ahead forward, I think we will hold on to it even if it, at least if it doesn't even improve, it will remain at the same level."

Specialty & Branded Transformation

Parag Sancheti: "if you look from 2007, there have been no new approvals for that product. Now, going with that definition, that just gives you a reflection of the kind of portfolio we have built up."

Manufacturing Capacity & Pithampur


Quality & Compliance Moat

Parag Sancheti: "we engage with the regulators very, very proactively. For example, in 2024, we went through a unique program called Quality Maturity Model which was a program which was launched by the FDA first time. It was a voluntary participation. We believe we were the only company from India and amongst the 32 companies which applied globally, we got selected from that which comprised of companies from both innovator side, large CDMOs like Catalan, Thermo Fisher, on the brand side companies like AstraZeneca, GSK and we were one of the eight companies selected..."

Pipeline, Capabilities & Strategic Bets

Parag Sancheti: "we don't subscribe to the view that the formulations business can be built by API integration. So from that, we are very, very clear that what we have done, current performance or the future performance is not dependent on API integration. So we definitely don't subscribe to the view that at a certain scale, you require API integration."

Guidance & Commitments

CommitmentSpecificsTimeline
Pithampur plant operationalizationFacility to be qualified, approved, and taking batchesMid-2026, ramp-up in Q1 CY27
EBITDA margin sustainEBITDA margin to sustain at current levels (~22.9%) even as gross margin trends toward 68%Ongoing, incorporates Pithampur operational costs
R&D spend rangeR&D expenditure at 10% to 11% of operating revenueNext 3 to 4 years
Portfolio concentrationShare of top 10 products to remain south of 60%Coming quarters
Outsourced manufacturing trendElevated outsourced manufacturing revenue to continueUntil Pithampur plant ramps up
Minority stake transaction disclosuresDisclosures to be made once approvals are receivedAt the appropriate time

Key Metrics

MetricQ2 FY26
Revenue growth39% YoY
Operating EBITDA growth53% YoY
PAT growth56% YoY
Gross margin68.7%, sequential and YoY decline driven by increased outsourced manufacturing
EBITDA margin22.9%, improved sequentially and YoY; expected to sustain at current levels
R&D expenditure11.2% of operating revenue; expected at 10–11% over next 3–4 years
Cash flow from operations₹60.5 cr
Annualized ROACE36%
Specialty products share of gross profitJust under 33%, compared to 13% in FY23
USD revenue growth (constant currency)33% YoY and 11.9% QoQ
Top 5 products contribution30% of revenue, down from 35% in Q1 FY26
Top 10 products contribution51% of revenue, down from 56% in Q1 FY26
Approved portfolio73 ANDAs and 9 NDAs as of 30 Sep 2025
Products commercialized76 of 82 approved products as of 30 Sep 2025
Commercialization rate93%
Non-productive R&DLess than 5%
US FDA-approved intranasal spray products5 as of 30 Sep 2025
Validus branded products marketed3 products with no competition; 2 launched from pipeline in 2025